Nuvation Bio Inc. (NUVB) Reports Q4 Loss, Beats Revenue Estimates
Nuvation Bio (NUVB) delivered earnings and revenue surprises of -2.33% and +52.63%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?